5HT2A / AD-PD DEMENTIA

Targeting 5HT2A Signaling to Address Alzheimer's and Parkinson’s Associated Dementia

Hallucinations and delusions are common in Alzheimer’s and Parkinson’s disease–associated dementia, creating a significant burden for patients and caregivers. Targeting 5HT2A signaling has been clinically validated as an effective approach to reducing these symptoms.

Sero Pharmaceuticals is advancing a highly selective 5HT2A inhibitor designed to precisely modulate serotonergic signaling while improving safety and tolerability through next-generation chemistry.

THE PROBLEM

Dementia-Related Psychosis Remains a Major Clinical Challenge

Neuropsychiatric symptoms such as hallucinations and delusions affect a substantial portion of patients with Alzheimer’s and Parkinson’s disease–associated dementia, contributing to disease progression, caregiver burden, and institutionalization.

The approval of pimavanserin (Nuplazid®) showed that 5HT2A inhibitor reduces psychosis without worsening motor symptoms. However, current therapies are limited by safety issues, such as QT interval prolongation from hERG potassium channel inhibition. This highlights the need for safer next-generation serotonergic treatments.

MARKET SIZE

A Growing Market Opportunity in Dementia-Related Psychosis

WW / TAM

$ 0 B+

WW / SAM

$ 0 B+

US / SOM

$ 0 B+

THE STATISTICS

Dementia-Related Psychosis Represents a Significant Unmet Medical Need

Hallucinations and delusions are common in Alzheimer’s and Parkinson’s disease–related dementia, significantly affecting patients, caregivers, and outcomes.

Targeting the 5HT2A receptor has been clinically validated as an effective approach for reducing psychosis symptoms without worsening motor function.

Pimavanserin (Nuplazid®) demonstrated the therapeutic relevance of 5HT2A inhibitor, establishing serotonergic modulation as a viable treatment pathway.

Safety challenges remain, including QT interval prolongation from hERG inhibition and added cardiovascular risk in vulnerable patients.

Current treatment options require careful monitoring and patient selection, underscoring the need for safer, more selective next-generation therapies.

OUR SOLUTION

A Next-Generation 5HT2A Inverse Agonist Designed for Precision and Safety

Designed without hERG potassium channel inhibition, minimizing the risk of QT interval prolongation and associated cardiac safety concerns.

Improved safety and tolerability profile, designed for chronic use in vulnerable populations with neurodegenerative diseases.

Advanced medicinal chemistry designed to preserve efficacy while reducing cardiovascular risk.

Centrally targeted pharmacology designed to minimize peripheral receptor engagement and off-target effects.

Dual 5HT2A / 5HT2C inhibitor that may support broader therapeutic potential across neuropsychiatric disorders.

COLLABORATE

Working Toward Safer Treatments for Dementia-Related Psychosis

We are developing a selective 5HT2A therapy for safer treatment of Alzheimer’s and Parkinson’s dementia. Connect with us to learn more about our research and partnership opportunities.